Sponsor or institution

Clinical trials and research at Daiichi Sankyo

• 34Clinical trials
• 1New in 30 days
• 41Countries

Newest trials

All recruiting trials (34)

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• DS-3939a in solid tumors and non-small cell lung cancer

  This study tests DS-3939a, alone or with other anticancer drugs, in adults with solid tumors including locally advanced or metastatic NSCLC to see if it is safe and helps control the disease.

  Recruiting at 3 sites Phase 1/2 Daiichi Sankyo · Fayetteville, Arkansas and 75 other locations · NCT07739966

• HER3-DXd and T-DXd combo therapy in HR-positive, HER2-low/ultralow breast cancer

  This trial tests a combination of patritumab deruxtecan and trastuzumab deruxtecan in people with HR-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer to see if it is safe and shows anti-tumor activity.

  Recruiting at 7 sites Phase 1/2 Daiichi Sankyo · Los Angeles, California and 71 other locations · NCT07701941

• T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer

  This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.

  Recruiting at 5 sites Phase 3 Daiichi Sankyo · Columbia, Maryland and 4 other locations · NCT07683754

• DS1025a: first-in-human test in advanced solid tumors

  This first-in-human trial tests DS1025a in adults with advanced, metastatic, or unresectable solid tumors to see if it is safe and tolerable and to look for early signs of activity.

  Recruiting at 3 sites Phase 1 Daiichi Sankyo · Kashiwa and 2 other locations · NCT07681882

• Valemetostat plus darolutamide for metastatic castration‑resistant prostate cancer

  This trial tests whether combining valemetostat with darolutamide is safe and tolerable for men whose prostate cancer has spread and no longer responds to hormone therapy.

  Recruiting at 29 sites Phase 1 Daiichi Sankyo · La Jolla, California and 28 other locations · NCT07244341

• First-in-human test of DS3790a for hematological malignancies

  This first-in-human trial will test DS3790a alone and with other drugs to see if it's safe, how it behaves in the body, and whether it helps adults with hematological malignancies.

  Recruiting at 8 sites Phase 1/2 Daiichi Sankyo · New York, New York and 7 other locations · NCT07220616

• Bempedoic Acid With Ezetiimibe in Adults with High Cholesterol or Mixed Dyslipidemia

  This study tests bempedoic acid alone or with ezetimibe in real-world adults with primary hypercholesterolemia or mixed dyslipidemia to see how safe and effective it is in routine care.

  Recruiting at 38 sites Daiichi Sankyo · Belo Horizonte and 37 other locations · NCT07206472

• DS9051b for advanced or metastatic adrenocortical carcinoma and metastatic castration‑resistant prostate cancer

  This trial will try an experimental drug called DS9051b in adults with advanced adrenocortical carcinoma or metastatic castration‑resistant prostate cancer to see if it is safe and shows early signs of benefit.

  Recruiting at 4 sites Phase 1 Daiichi Sankyo · Sarasota, Florida and 5 other locations · NCT07189403

• DS5361b alone and with pembrolizumab for adults with advanced solid tumors

  This trial will test whether the new drug DS5361b, given alone or with pembrolizumab, is safe and shows signs of benefit in adults with advanced or metastatic solid tumors that have high tumor mutational burden or microsatellite instability.

  Recruiting at 7 sites Phase 1 Daiichi Sankyo · Sarasota, Florida and 6 other locations · NCT07182591

• DS3610a for adults with advanced or metastatic solid tumors

  This trial will test whether DS3610a is safe and helps adults with advanced or metastatic solid tumors.

  Recruiting at 4 sites Phase 1 Daiichi Sankyo · Milwaukee, Wisconsin and 3 other locations · NCT07159126

• Datopotamab deruxtecan plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin for advanced or metastatic urothelial carcinoma

  This trial will test whether datopotamab deruxtecan with carboplatin or cisplatin works better than gemcitabine with carboplatin or cisplatin for people with advanced urothelial carcinoma who progressed during or after enfortumab vedotin plus pembrolizumab.

  Recruiting at 29 sites Phase 2/3 Daiichi Sankyo · Fullerton, California and 99 other locations · NCT07129993

• Trastuzumab deruxtecan versus standard chemotherapy for HER2-expressing (IHC 3+/2+) endometrial cancer

  This trial tests trastuzumab deruxtecan versus standard chemotherapy after surgery for adults with newly diagnosed HER2-expressing (IHC 3+/2+) endometrial cancer.

  Recruiting at 86 sites Phase 3 Daiichi Sankyo · Fort Lauderdale, Florida and 85 other locations · NCT07022483

• Subcutaneous trastuzumab deruxtecan plus hyaluronidase for metastatic solid tumors

  This trial tests whether a subcutaneous form of trastuzumab deruxtecan given with hyaluronidase is safe and works for adults with recurrent or metastatic solid tumors.

  Recruiting at 26 sites Phase 1 Daiichi Sankyo · Newport Beach, California and 30 other locations · NCT07015697

• Trastuzumab deruxtecan plus pembrolizumab versus platinum chemotherapy plus pembrolizumab for first-line HER2‑overexpressing non‑squamous NSCLC

  This trial will test whether combining trastuzumab deruxtecan with pembrolizumab works better than standard platinum‑based chemotherapy plus pembrolizumab as first treatment for adults with HER2‑overexpressing, PD‑L1 low (<50%) advanced non‑squamous NSCLC.

  Recruiting at 246 sites Phase 3 Daiichi Sankyo · Anchorage, Alaska and 245 other locations · NCT06899126

• Evaluating the effectiveness and safety of Trastuzumab Deruxtecan in advanced HER2-positive gastric cancer in China

  This study is testing how well Trastuzumab Deruxtecan works and how safe it is for people in China with advanced HER2-positive stomach cancer who are already receiving this treatment.

  Recruiting at 34 sites Daiichi Sankyo · Beijing and 39 other locations · NCT06846996

• Quizartinib maintenance at two doses for FLT3‑ITD positive AML in first complete remission

  This trial tests whether two different doses of quizartinib can help prevent relapse in adults with FLT3‑ITD positive AML who are in first complete remission and have not had an allogeneic stem cell transplant.

  Recruiting at 50 sites Phase 2 Daiichi Sankyo · Birmingham, Alabama and 63 other locations · NCT06824168

• Combining Trastuzumab Deruxtecan with Bevacizumab for Ovarian Cancer Treatment

  This study is testing if combining two drugs, Trastuzumab Deruxtecan and Bevacizumab, can help people with advanced ovarian cancer feel better compared to using Bevacizumab alone.

  Recruiting at 232 sites Phase 3 Daiichi Sankyo · Burbank, California and 231 other locations · NCT06819007

• Effectiveness and safety of T-DXd in Chinese patients with HER2 mutation-positive lung cancer

  This study is testing how well and safely a drug called T-DXd works for Chinese patients with advanced lung cancer that has HER2 mutations.

  Recruiting at 29 sites Daiichi Sankyo · Beijing and 35 other locations · NCT06809764

• Evaluating quizartinib in patients with severe liver impairment

  This study is testing how a single dose of quizartinib affects people with severe liver problems compared to healthy individuals to see if it's safe and how the body processes the medication.

  Recruiting at 3 sites Phase 1 Daiichi Sankyo · Miami, Florida and 2 other locations · NCT06740799

• Combination treatment for advanced HER2-positive gastric cancer

  This study is testing a new combination treatment for adults with advanced HER2-positive gastric cancer to see if it works better than the standard treatment.

  Recruiting at 219 sites Phase 3 Daiichi Sankyo · New Haven, Connecticut and 249 other locations · NCT06731478

• Evaluating ifinatamab deruxtecan for advanced esophageal cancer

  This study is testing a new drug called ifinatamab deruxtecan to see if it helps people with advanced esophageal cancer who haven't responded to other treatments live longer and feel better compared to those getting standard chemotherapy.

  Recruiting at 167 sites Phase 3 Daiichi Sankyo · Phoenix, Arizona and 167 other locations · NCT06644781

• Testing DS-2243a for advanced solid tumors

  This study is testing a new treatment called DS-2243a to see if it helps people with advanced solid tumors like certain types of sarcoma, lung cancer, and bladder cancer.

  Recruiting at 7 sites Phase 1 Daiichi Sankyo · Boston, Massachusetts and 6 other locations · NCT06644755

• Evaluating a new treatment for extensive stage-small cell lung cancer

  This study is testing a new treatment combining ifinatamab deruxtecan and atezolizumab, with or without carboplatin, to see if it can help people with extensive stage-small cell lung cancer feel better and improve their treatment results.

  Recruiting at 55 sites Phase 1/2 Daiichi Sankyo · Birmingham, Alabama and 57 other locations · NCT06362252

• Evaluating Ifinatamab Deruxtecan for Recurrent or Metastatic Solid Tumors

  This study is testing a new drug called ifinatamab deruxtecan to see if it can help people with recurrent or metastatic solid tumors that have already been treated.

  Recruiting at 104 sites Phase 1/2 Daiichi Sankyo · Los Angeles, California and 119 other locations · NCT06330064

• Assessing Trastuzumab Deruxtecan in Chinese Patients with HER2-positive and HER2-low Breast Cancer

  This study is testing how well Trastuzumab Deruxtecan works for Chinese patients with advanced HER2-positive or HER2-low breast cancer who have already tried other treatments.

  Recruiting at 46 sites Daiichi Sankyo · Beijing and 53 other locations · NCT06210776

• Comparing Ifinatamab Deruxtecan to Physician's Choice for Relapsed Small Cell Lung Cancer

  This study is testing if a new drug called Ifinatamab deruxtecan can help people with relapsed small cell lung cancer more than the treatments their doctors usually choose.

  Recruiting at 189 sites Phase 3 Daiichi Sankyo · Springdale, Arkansas and 228 other locations · NCT06203210

• Continued access to treatment for patients with advanced cancer

  This study is testing if patients with advanced cancer who have benefited from previous treatments can safely continue receiving a specific drug to see if it helps them longer.

  Recruiting Phase 3 Daiichi Sankyo · Miami, Florida and 33 other locations · NCT06174987

• Investigating HER3-DXd for advanced solid tumors

  This study is testing a new drug called HER3-DXd to see if it can safely help people with advanced solid tumors like melanoma, head and neck cancer, and gastric cancer who have already tried other treatments.

  Recruiting at 92 sites Phase 2 Daiichi Sankyo · Duarte, California and 95 other locations · NCT06172478

• Raludotatug Deruxtecan (R-DXd) for platinum-resistant high-grade ovarian, fallopian tube, and primary peritoneal cancer

  This trial will test whether R-DXd helps people with platinum-resistant high-grade ovarian, fallopian tube, or primary peritoneal cancer who have stopped responding to platinum chemotherapy.

  Recruiting at 29 sites Phase 2/3 Daiichi Sankyo · Anchorage, Alaska and 166 other locations · NCT06161025

• Evaluating trastuzumab deruxtecan for patients with low HER2 metastatic breast cancer

  This study is testing a new drug called trastuzumab deruxtecan to see if it can help people with low HER2 metastatic breast cancer live longer before needing a different treatment.

  Recruiting at 68 sites Phase 3 Daiichi Sankyo · Miami Beach, Florida and 87 other locations · NCT05950945

• Observational study on HER2-low breast cancer treatment with Trastuzumab Deruxtecan

  This study is testing how well Trastuzumab deruxtecan works for adults with advanced HER2-low breast cancer who have already had chemotherapy.

  Recruiting at 26 sites Daiichi Sankyo · Graz and 215 other locations · NCT05945732

• Testing DS-3939a for advanced solid tumors

  This study is testing a new drug called DS-3939a to see if it can safely help people with advanced solid tumors feel better.

  Recruiting at 43 sites Phase 1/2 Daiichi Sankyo · Sarasota, Florida and 60 other locations · NCT05875168

• DS-1103a combo therapy in advanced solid tumors

  This study tests DS-1103a in combination with other anticancer therapies to see if it’s safe and helps people with advanced solid tumors.

  Recruiting at 15 sites Phase 1 Daiichi Sankyo · Sarasota, Florida and 14 other locations · NCT05765851

Quick answers

How many clinical trials run by Daiichi Sankyo are recruiting right now?

34, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 41 countries. The most sites are in United States (27 trials), France (23 trials), Japan (22 trials), Spain (19 trials), China (18 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 9, Phase 1: 9, Phase 1/2: 7, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →